Transforming the course
to help people
Live The Best Day,
Immune-mediated inflammatory diseases are
responsible for a significant health burden to
patients and society.1 That’s why our research
is primarily centred around the biology of
the immune system. Our aim is to develop
immune-based therapies that have the potential
to alter the course of inflammatory disease.
From Today’s Reality,
to Tomorrow’s Vision
As part of our commitment to help people
with lupus, hear from the “Vision for Lupus*”
Steering Committee as they highlight
inconsistencies in care and outline key
calls to action, providing insights into the
implementation of multidisciplinary care.
Friday, June 14th 8h15-9h45
Reference: 1. Jacobs P, Bissonnette R, Guenther LC. Socioeconomic burden
of immune-mediated inflammatory diseases: focusing on work productivity and
disability. J Rheumatol Suppl 2011;88:55-61.
GSK conceived, developed and led this report in collaboration with a Global
Steering Committee who received a fee for their services. GSK had editorial
input into this document.
©2019 GSK group of companies. All rights reserved.
NP-GBL-BEL-ADVT-190006 Date of preparation: March 2019